Table 2.
Albuminuria strata and risk of cardiovascular disease, mortality and dialysis outcomes
| Urine ACR Category | Continuous: Per ACR doubling* |
||||
|---|---|---|---|---|---|
| < 10 mg/g (n=1017) |
10-<30 mg/g (n=912) |
30-<300 mg/g (n=1134) |
>=300 mg/g (n=448) |
||
| Allograft Failure | |||||
| Unadjusted | 1.00 (ref) | 1.27 (0.74, 2.16) | 4.46 (2.91, 6.83) |
15.00 (9.81, 22.94) |
1.47 (1.40, 1.54) |
| Parsimonious Adjusted |
1.00 (ref) | 1.32 (0.77, 2.25) | 4.63 (3.02, 7.10) |
14.89 (9.66, 22.96) |
1.48 (1.41, 1.56) |
| Extended Adjusted | 1.00 (ref) | 1.24 (0.73, 2.11) | 3.40 (2.19, 5.30) |
9.96 (6.35, 15.62) |
1.43 (1.36, 1.51) |
| Cardiovascular Disease | |||||
| Unadjusted | 1.00 (ref) | 1.16 (0.89, 1.52) | 1.65 (1.30, 2.09) |
2.29 (1.74, 3.02) | 1.11 (1.08, 1.15) |
| Parsimonious Adjusted |
1.00 (ref) | 1.09 (0.84, 1.43) | 1.68 (1.32, 2.15) |
2.44 (1.83, 3.25) | 1.12 (1.09, 1.17) |
| Extended Adjusted | 1.00 (ref) | 0.99 (0.75, 1.29) | 1.25 (0.96, 1.61) |
1.55 (1.13, 2.11) | 1.06 (1.02, 1.10) |
| All-Cause Mortality | |||||
| Unadjusted | 1.00 (ref) | 1.23 (0.90, 1.68) | 2.25 (1.71, 2.95) |
2.98 (2.18, 4.09) | 1.18 (1.14, 1.23) |
| Parsimonious Adjusted |
1.00 (ref) | 1.09 (0.79, 1.49) | 2.05 (1.56, 2.71) |
2.80 (2.02, 3.89) | 1.18 (1.13, 1.22) |
| Extended Adjusted | 1.00 (ref) | 1.02 (0.74, 1.39) | 1.65 (1.23, 2.21) |
2.07 (1.46, 2.94) | 1.13 (1.09, 1.18) |
| Allograft Failure or All-Cause Mortality | |||||
| Unadjusted | 1.00 (ref) | 1.28 (0.97, 1.70) | 2.84 (2.24, 3.61) |
6.25 (4.84, 8.07) | 1.30 (1.27, 1.34) |
| Parsimonious Adjusted |
1.00 (ref) | 1.23 (0.93, 1.64) | 2.76 (2.17, 3.53) |
6.04 (4.64, 7.87) | 1.30 (1.26, 1.34) |
| Extended Adjusted | 1.00 (ref) | 1.17 (0.88, 1.56) | 2.20 (1.71, 2.83) |
4.55 (3.46, 5.99) | 1.26 (1.22, 1.31) |
ACR of <10 mg/mg is considered normal; 10-<30 mg/mg is considered high-normal (mildly increased); 30-<300 mg/g is moderately increased; >=300 mg/g is severely increased
Rates are unadjusted. Models present the hazard ratio (95% confidence interval). The parsimonious model is adjusted for age, sex, race, study allocation, country, graft vintage, donor type, calcineurin inhibitor use and sirolimus use, aspirin use, and statin use, while the extended model is adjusted for age, sex, race, study allocation, country, graft vintage, donor type, calcineurin inhibitor use, sirolimus use, diabetes, history of cardiovascular disease, smoking status, systolic blood pressure, diastolic blood pressure, body mass index, HDL cholesterol, LDL cholesterol, triglycerides, angiotensin converting enzyme inhibitor or angiotensin receptor blocker use, aspirin use, statin use, and estimated GFR. PY, person-year.
based on data from participants in all ACR categories